TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10201422
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day mianserin
Study: 2213394
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (0.15 mg/kg/dose)
Study: 468583
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (3x5000 IU, starting 2 hours preoperatively)
Study: 468583
Drug: Intravenous dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextran (3x500 ml of 6% dextran 70)
Study: 24069230
Drug: Opal-HIV-Gag(c) 12
Normalized name: carbetapentane tannate / chlorpheniramine tannate Oral Suspension [C-Tanna 12]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opal-HIV-Gag(c) 12 mg
Study: 24069230
Drug: Opal-HIV-Gag(c) 24
Normalized name: C.i. solvent red 24
DrugBank: Scarlet red (DB19136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opal-HIV-Gag(c) 24 mg
Study: 24069230
Drug: Opal-HIV-Gag(c) 48
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opal-HIV-Gag(c) 48 mg
Study: 21840601
Drug: Tacrolimus 0.5
Normalized name: tacrolimus 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.5 mg capsules
Study: 21840601
Drug: Tacrolimus 5
Normalized name: tacrolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 5 mg capsules
Study: 21840601
Drug: Tacrolimus test
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus test formulations
Study: 19150378
Drug: Neonatal 7-valent
Normalized name: calcium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neonatal 7-valent pneumococcal conjugate vaccine (7vPCV)
Study: 18044435
Drug: One dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose, vaccinated once at reimplant (day 42)
Study: 18044435
Drug: Two doses,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses, vaccinated on arrival (day 0) and again at reimplant (day 42)
Study: 18044435
Drug: Three doses,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses, vaccinated on arrival (day 0), on day 21, and again at reimplant (day 42)
Study: 9872488
Drug: Nifedipine (30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30‐60 mg/day) for mild to moderate hypertension for at least 1 year
Study: 23542611
Drug: 360 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg/m2 epratuzumab
Study: 23542611
Drug: 720 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mg/m2 epratuzumab
Study: 23542611
Drug: 360 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg/m2 epratuzumab in SL0006
Study: 11337625
Drug: Methylprednisolone and
Normalized name: methylprednisolone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone and bupivacaine combination
Study: 3310586
Drug: Moricizine HCl
Normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine HCl (816 ± 103 mg daily)
Study: 3310586
Drug: Moricizine HCl
Normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine HCl (800 mg daily)
Study: 3310586
Drug: Disopyramide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (600 mg daily)
Study: 29895491
Drug: Silymarin 140
Normalized name: silymarin 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140 mg, thrice daily for 45 days
Study: 28539413
Drug: Unconditional cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconditional cash transfers (UCT) of 10,000 West African Financial Community of Africa francs (∼US$17) provided monthly from July to November over 2 years (2013 and 2014).
Study: 12690216
Drug: Dexmedetomidine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (target plasma level 0.4 ng/mL)
Study: 12690216
Drug: Meperidine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (target plasma level 0.3 microg/mL)
Study: 12690216
Drug: Meperidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine plus dexmedetomidine (target plasma levels of 0.3 microg/mL and 0.4 ng/mL)
Study: 29171139
Drug: linagliptin 1
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 1 mg
Study: 27643296
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + Amlodipine 5 mg (L/A group)
Study: 27643296
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + Hydrochlorothiazide 12.5 mg (L/H group)
Study: 27643296
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + Amlodipine 100 mg (L/A group)
Study: 27643296
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + Hydrochlorothiazide 100 mg (L/H group)
Study: 18762494
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray with counseling for 8 weeks
Study: 18762494
Drug: Weekly counseling
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly counseling alone for 8 weeks
Study: 15983465
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion (30-min duration)
Study: 15983465
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (30-min duration)
Study: 7049584
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acebutolol alone
Study: 7049584
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acebutolol + hydrochlorothiazide/amiloride diuretic
Study: 7049584
Drug: hydrochlorothiazide/amiloride diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide/amiloride diuretic
Study: 21424274
Drug: Level run
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level run (L)
Study: 14685830
Drug: NON OP
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: NON OP (non-operative therapy)
Study: 7307591
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no indomethacin therapy)
Study: 31627746
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and surgery
Study: 30651130
Drug: Trans-tympanic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-tympanic injection of sodium thiosulfate gel in the left or right ear
Study: 30651130
Drug: Control ears
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ears (no treatment)
Study: 28340430
Drug: Bilateral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sequential stimulation (BSS) with theta burst stimulation (TBS)
Study: 24856433
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (after 2 hours)
Study: 24856433
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral feeding (after 18 hours)
Study: 22612913
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and exercises (N = 33)
Study: 19528286
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg PA-824
Study: 19528286
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg PA-824
Study: 14674937
Drug: Allergen specific
Normalized name: Allergen specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen specific immunotherapy (SIT) with standardized birch pollen extract
Study: 7646570
Drug: Quinidine sulphate
Normalized name: Quinidine sulphate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulphate 250 mg administered at 10:00 h
Study: 7646570
Drug: Quinidine sulphate
Normalized name: Quinidine sulphate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulphate 250 mg administered at 22:00 h
Study: 28514527
Drug: Robenacoxib (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robenacoxib (2.0 mg/kg SC injection prior to surgery and for 2 additional days postoperatively)
Study: 28514527
Drug: Placebo (SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (SC injection prior to surgery and for 2 additional days postoperatively)
Study: 18210765
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus metformin
Study: 12037435
Drug: Low-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose botulinum toxin (BTX) treatment (mean total target dose of 547 +/- 113 mouse units)
Study: 12037435
Drug: 4-times-diluted preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-times-diluted preparation (130 +/- 32 MU)
Study: 7486097
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine (4 micrograms/kg in 10 mL) infused in 20 min followed by a 2-micrograms.kg-1.h-1 infusion (5 mL/h) during 12 h (Group 1)
Study: 7486097
Drug: Sufentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.5 microgram/kg in 10 mL) in 20 min followed by a 0.25-microgram.kg-1.h-1 infusion (5 mL/h) during 12 h (Group 2)
Study: 2137971
Drug: Nafarelin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin, 400 and 800 micrograms administered intranasally
Study: 2137971
Drug: Danazol, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol, 600 and 800 mg
Study: 6770408
Drug: Alcohol 0.45
Normalized name: ALCOHOL 0.45 mL in 1 mL TOPICAL LIQUID [Decolorized Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.45 ml/kg
Study: 6770408
Drug: Alcohol 0.90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.90 ml/kg
Study: 6770408
Drug: Combined alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined alcohol (0.45 ml/kg and 0.90 ml/kg) and sleep deprivation (26 h)
Study: 6770408
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 ml/kg alcohol and no sleep deprivation)
Study: 30370852
Drug: Fomentex herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fomentex herbal tea 11.2 g/day in 2 divided doses for 2 weeks
Study: 30370852
Drug: Medroxy progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medroxy progesterone acetate (MP) 10 mg/day for the last 10 days of their menstrual cycles
Study: 28962586
Drug: Treatment intensification
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensification (methotrexate + tapered high-dose prednisone)
Study: 23665027
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg QD
Study: 19250050
Drug: Ga‐As laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga‐As laser therapy combined with a 12‐wk comprehensive home exercise program
Study: 9814462
Drug: T4 (levothyroxine)
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 (levothyroxine) treatment (21 patients, 2.7 +/- 0.3 microg/kg, TSH < 0.3 microIU/mL)
Study: 9814462
Drug: T4 (levothyroxine)
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 (levothyroxine) treatment
Study: 2473363
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy [3 X (COPP + ABVD)]
Study: 2473363
Drug: Chemotherapy [1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy [1 X (COPP + ABVD)]
Study: 28584913
Drug: Triazolam 0.0625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.0625 mg
Study: 17461726
Drug: (32)P‐chromic phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: (32)P‐chromic phosphate colloids (32)P‐CP) administered via multipointed infiltrative injection
Study: 17461726
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (simple operative group without (32)P‐CP injection)
Study: 16602632
Drug: Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin treatment for two months
Study: 7604799
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg once daily for 4 weeks, then 40 mg twice daily for 12 weeks
Study: 7604799
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg once daily for 4 weeks, then 40 mg once daily for 12 weeks
Study: 2227077
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketorolac given orally every 6 h for up to 7 days
Study: 2227077
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pentazocine given orally every 6 h for up to 7 days
Study: 452941
Drug: Mefruside (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefruside (25 mg daily)
Study: 452941
Drug: Atenolol (100–400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100–400 mg daily)
Study: 31945586
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (1 ng/kg/min)
Study: 30114658
Drug: oxaliplatin-fluoropyrimidine chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin-fluoropyrimidine chemotherapy with cetuximab
Study: 30114658
Drug: oxaliplatin-fluoropyrimidine chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin-fluoropyrimidine chemotherapy
Study: 20226404
Drug: Laparoscopic cystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cystectomy with the vasopressin injection technique
Study: 20226404
Drug: Ordinary laparoscopic
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary laparoscopic cystectomy without injection
Study: 20226404
Drug: Laparoscopic cystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cystectomy with the injection of saline solution
Study: 19112723
Drug: Metoprolol (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (starting dose 50 mg bid)
Study: 19112723
Drug: Clonazepam (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (starting dose 0.5 mg qd)
Study: 16181303
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg (once per day)
Study: 12719203
Drug: Aspirin (low-risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (low-risk patients)
Study: 12719203
Drug: Aspirin (validation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (validation set low-risk patients)
Study: 12719203
Drug: Therapeutic oral
Normalized name: multivitamin,therapeutic ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic oral anticoagulation therapy (low-risk patients)
Study: 8723141
Drug: FCE 23,884
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 23,884 monotherapy (3.5 +/- 0.5 mg)
Study: 8723141
Drug: FCE 23,884
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 23,884 coadministered with a mildly dyskinetic dose of levodopa
Study: 6685515
Drug: standard oxazepam
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard oxazepam formulation
Study: 29344631
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) - 12 sessions, 60 minutes each
Study: 29344631
Drug: Written Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written Exposure Therapy (WET) - 5 sessions, 60 minutes for the first session and 40 minutes for the remaining sessions
Study: 22431582
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust exposure (200 μg/m(3) of fine particulate matter) for 120 minutes
Study: 17997151
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 300 mg tenofovir disoproxil fumarate with 200 mg emtricitabine
Study: 15486039
Drug: Ketorolac (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (45 mg)
Study: 12214151
Drug: 10-20 mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mg quinapril for 6 months
Study: 12214151
Drug: 50-100 mg
Normalized name: insulin lispro protamine, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-100 mg losartan for 6 months
Study: 26646828
Drug: Metacognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive therapy programme
Study: 16943462
Drug: Palamed G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palamed G
Study: 10809243
Drug: Immediate full-volume
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate full-volume exchange (2000 mL) per 6 hours from the day of catheter implantation (group 2)
Study: 1516840
Drug: cold perfusate
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold perfusate + EC‐SOD C 10.4 mg/L (30,000 U/L)
Study: 1516840
Drug: cold perfusate
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold perfusate + bovine CuZn‐SOD 7.5 mg/L (30,000 U/L)
Study: 1516840
Drug: cold perfusate
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold perfusate + EC‐SOD C 10.4 mg/L + heparin 50,000U/L
Study: 1516840
Drug: cold perfusate
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold perfusate + heparin 50,000 U/L
Study: 1516840
Drug: cold perfusate
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold perfusate only, cold perfusate + bovine CuZn‐SOD, cold perfusate + EC‐SOD C + heparin, cold perfusate + heparin
Study: 6707844
Drug: Full-strength cow's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength cow's milk feeds after 24 hours of GEM treatment
Study: 28857654
Drug: Duloxetine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine therapy for 12 weeks
Study: 15041596
Drug: Preincision ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincision ketamine 0.15 mg/kg
Study: 15041596
Drug: Postoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative ketamine 0.15 mg/kg
Study: 7942164
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 or 2000 mg Ca2+)
Study: 2904754
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean dose, 3.3 mg) once daily for 8 weeks
Study: 2904754
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) once daily for 8 weeks
Study: 26758116
Drug: Methylprednisolone 2
Normalized name: methylprednisolone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 2 mg/(kg·d) intravenously for 3 days
Study: 26758116
Drug: Non-steroid therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid therapy
Study: 22028266
Drug: Fendrix (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendrix (20 micrograms, 4 doses)
Study: 22028266
Drug: Engerix B
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix B (40 micrograms, 3 doses with optional booster)
Study: 11185674
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg QD for 10 days)
Study: 11185674
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg once daily on days 4 through 10) with Rofecoxib
Study: 2860386
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg CL115,347/day transdermally for 6 weeks
Study: 30624598
Drug: 6-month hypocaloric,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month hypocaloric, nutritionally complete, higher-protein meal plan targeting ≥1.0 g protein · kg body weight-1 · d-1 (WL group; n=47)
Study: 30624598
Drug: Weight-stability (WS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-stability (WS) group targeting 0.8 g protein · kg body weight-1 · d-1 (n=49)
Study: 26993331
Drug: C. difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. difficile vaccine formulations (toxoids A and B) administered at antigen dose levels of 50, 100, or 200 μg in a 3-dose regimen at 0, 1, and 6 months.
Study: 22782417
Drug: Acadesine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine (0.1 mg/kg per minute for 7 hours)
Study: 21311486
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (copaxone) 20 mg/d for 4.3±2.6 years
Study: 21311486
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with confirmed MS in remission not treated with disease-modifying drugs
Study: 10332798
Drug: Passive control
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive control treatment
Study: 2044395
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg bencyclane twice daily
Study: 28644575
Drug: Levofloxacin plus
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin plus bismuth‐based quadruple therapy (RBAL)
Study: 28644575
Drug: Levofloxacin‐based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin‐based triple therapy (RAL)
Study: 23984728
Drug: Macitentan 3
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 3 mg
Study: 16860698
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor (efavirenz, EFV)
Study: 16860698
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (nelfinavir, NFV)
Study: 12664518
Drug: Oral Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tramadol 0.5 mg/kg/6 hours for 24 hours